TRAIL Biomarker Risk Stratification for Viral Infection Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing viral infection patients lack a reliable biomarker to differentiate between low-risk and high-risk patients, leading to inappropriate treatment and resource allocation.
Innovation Solution
Measuring TNF-related apoptosis-inducing ligand (TRAIL) protein levels in blood samples to determine the risk category of viral infection patients, with predetermined thresholds guiding treatment decisions from intensive care to hospital release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to manage viral infection patients, then treatment and resource allocation are performed, but there is no reliable biomarker to differentiate between low-risk and high-risk patients leading to inappropriate treatment
Solution Approach 1:
The patent introduces TRAIL protein as an intermediary biomarker that mediates between the viral infection state and patient risk assessment. By measuring TRAIL levels in blood samples, the system obtains reliable information about patient risk category, enabling appropriate differentiation between low-risk and high-risk patients and guiding subsequent treatment decisions.
2Reliability
If aggressive treatment is provided to all viral infection patients, then patient safety is improved, but resource allocation efficiency deteriorates due to unnecessary interventions
Solution Approach 1:
The patent applies local quality by tailoring treatment intensity to individual patient risk categories. Instead of uniform aggressive treatment for all patients, the system provides differentiated care: standard care for low-risk patients (identified by TRAIL levels above threshold) and aggressive treatment for high-risk patients (TRAIL levels below threshold), thereby optimizing resource allocation while maintaining patient safety where needed.
3Reliability
If aggressive treatment is provided to all viral infection patients, then patient safety is maintained, but unnecessary interventions increase leading to waste
Solution Approach 1:
The system implements local quality by matching treatment intensity to individual patient needs based on TRAIL biomarker levels. Low-risk patients (TRAIL above threshold) receive standard care avoiding unnecessary aggressive interventions and resource waste, while high-risk patients (TRAIL below threshold) receive aggressive treatment to ensure safety, thus eliminating medical resource waste while maintaining safety where required.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Accurately stratifies patients into low-risk and high-risk categories, optimizing treatment approaches and resource allocation by reducing unnecessary interventions and identifying those who can be safely discharged or require aggressive care.
Implementation Method 1
the measuring is determined electrophoretically or immunochemically
Implementation Method 2
the immunochemical determination is effected by lateral flow immunoassay, flow cytometry, radioimmunoassay, immunofluorescence or by an enzyme-linked immunosorbent assay
Data Source
AI summary
A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is above a predetermined amount, the subject is treated as a low-risk patient.